Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc, pooled analysis from two placebo‐controlled trials
- 20 August 2012
- journal article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 31 (8) , 1258-1265
Abstract
Aims: To assess the efficacy and tolerability of fesoterodine 8 mg versus tolterodine extended release (ER) 4 mg in subjects with overactive bladder (OAB) stratified by age (<65, 65–74, and ≥75 years).Methods: This was a post hoc analysis of data from two double‐blind trials. Subjects reporting ≥1 urgency urinary incontinence (UUI) episode and ≥8 micturitions/24 hr at baseline were randomized to fesoterodine (4 mg for 1 week, 8 mg for 11 weeks), tolterodine ER 4 mg, or placebo. Subjects completed 3‐day bladder diaries, Urgency Perception Scale (UPS), Patient Perception of Bladder Condition (PPBC), and OAB questionnaire (OAB‐q) at baseline and week 12. The primary endpoint in both studies was change from baseline to week 12 in UUI episodes.Results: Among subjects <65 years (n = 2,670), improvements in UUI episodes, micturitions, urgency episodes, severe urgency episodes, frequency‐urgency sum, UPS, PPBC, and all OAB‐q scales and domains were significantly greater with fesoterodine versus tolterodine ER, and diary‐dry rates were significantly higher. Among subjects 65–74 years (n = 990), improvements in mean voided volume per void, PPBC, and OAB‐q Symptom Bother and Coping were significantly greater with fesoterodine versus tolterodine ER. Among subjects aged ≥75 years (n = 448), improvements in urgency episodes, severe urgency episodes, frequency‐urgency sum, UPS, and OAB‐q Symptom Bother were significantly greater with fesoterodine versus tolterodine ER. Both active treatments produced significant improvements in most outcomes versus placebo across age groups. Adverse event rates were similar among age groups.Conclusions: Fesoterodine 8 mg consistently improved several OAB‐related variables versus tolterodine ER 4 mg in subjects aged <65, 65–74, and ≥75 years, with some differences reaching statistical significance, and was generally well tolerated. Neurourol. Urodynam. 31:1258–1265, 2012.Keywords
Funding Information
- Pfizer, Inc.
This publication has 28 references indexed in Scilit:
- Dynamic Progression of Overactive Bladder and Urinary Incontinence Symptoms: A Systematic ReviewEuropean Urology, 2010
- Vulnerable Elderly Patients and Overactive Bladder SyndromeDrugs & Aging, 2010
- Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms: A Longitudinal Population-Based Survey in Men Aged 45–103 YearsEuropean Urology, 2010
- An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunctionNeurourology and Urodynamics, 2009
- Lower urinary tract symptoms: lack of change in prevalence and help‐seeking behaviour in two population‐based surveys of women in 1991 and 2007BJU International, 2009
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older AdultsArchives of internal medicine (1960), 2003
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Urinary Incontinence: Does it Increase Risk for Falls and Fractures?Journal of the American Geriatrics Society, 2000
- The Impact of Urge Urinary Incontinence on Quality of Life: Importance of Patients' Perspective and Explanatory StyleJournal of the American Geriatrics Society, 1998